Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy.

ABSTRACT: Cytokine release syndrome (CRS) is a systemic inflammatory response associated with chimeric antigen receptor T-cell (CAR-T) therapies. In severe cases, CRS can be associated with coagulopathy and hypofibrinogenemia. We present our global multicenter experience with CRS-associated coagulopathy after tisagenlecleucel therapy in 137 patients with relapsed or refractory B-cell acute lymphoblastic leukemia from the ELIANA and ENSIGN trials. These trials included clinical guidelines for fibrinogen replacement during CRS-associated coagulopathy. Hypofibrinogenemia requiring replacement was observed only in patients with severe CRS. A higher percentage of patients who required replacement were <10 years old, compared with those who did not require replacement. Twenty-three patients received repla

SUBMITTER: Buechner J 

PROVIDER: S-EPMC7839371 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature